Table of Contents
Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Competitive Analysis
- Profiles
Introduction
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Types of Therapeutic Vaccines
- Patient-Specific Vaccines
- Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART-1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
Cervical Cancer Vaccines
- Overview
- Vaccines Products
- On the Market
- Gardasil
- In Development
- Cervarix
- TG 4001
- Lovaxin C
- HspE7
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Colon/Rectal Cancer Vaccines
- Overview
- Vaccine Products
- On the Market
- OncoVAX
- In Development
- OncoVAX
- ALVAC -CEA/B7.1
- TroVAX
- Avicine
- Ep2101
- IGN 101
- Collidem
- Lapuleucel-T
- Oncophage
- CRS-100
- MDX-1307
- Tumor Associated Antigen Therapeutic Vaccine-HER-2 and CEA
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Lung Cancer Vaccines
- Overview
- Vaccine Products in Development
- Stimuvax
- ICN-101
- GV-1001
- Ep2101
- Oncophage
- PanVac + Taxotere
- MAGE-3 Peptide
- INGN 225
- TG 4010
- L-VAX
- ALT-110
- CEA-TriCom
- DC Vax
- Lapuleucel-T
- L523S
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Lymphoma Vaccines
- Overview
- Vaccines in Development
- MyVax
- BiovaxID
- FavId
- Oncophage
- TG4010
- FAV-201
- Non-Hodgkin' s Lymphoma Vaccine
- BGLP40 Vaccine
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Melanoma Vaccines
- Overview
- Vaccines on the Market
- Vaccines in Development
- M-VAX
- GMK
- Allovectin-7
- MDX-010/MDX-1379
- Oncophage
- Canvaxin
- Melacine
- Triple Peptide Vaccine
- MART-1/Melan-A
- MAGE-3 Peptide
- TriCom
- Tyrosinase Peptide
- Uvidem
- Melan-A/MART-1 and gp100
- ALVAC -CEA/B7.1
- MDX-1106/ONO-4538
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Prostate Cancer Vaccines
- Overview
- Vaccines in Development
- Provenge
- DC Vax-Prostate
- GVAX
- Stimuvax
- GnRH Pharmaccine Therapeutic Vaccine
- IGN-101
- Pentrix
- PROSTVAC-VF
- Telomerase Cancer Vaccine
- TG4010
- Norelin
- PSMA RS Protein Vaccine
- Luteinizing Hormone Releasing Hormone
- ALT-110
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Various Cancer Vaccines
- Overview
- Bladder Cancer
- Breast Cancer
- Stomach Cancer
- Liver Cancer
- Pancreatic Cancer
- Kidney Cancer
- Leukemia
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Sarcoma
- Vaccines on the Market
- BCG Therapy (OncoTICE- Organon Teknika; Immucyst-Sanofi Pasteur;
Pacis-Shire Pharmaceuticals)
- Vaccines in Development
- Oncophage
- Insegia
- Avicine
- MyVax
- PANVAC-VF
- Theratope
- Bexidem
- AG-858
- DC Vax
- GVAX
- IGN-101
- O-VAX Autologous Cell Vaccine
- PX 104.1
- TroVAX
- Dendritic Cell/Tumor Cell Fusion Cancer Vaccine
- INGN 225
- ALT-110
- DNA Cancer Vaccine
- GV 1001
- Lapuleucel-T
- Lovaxin C
- MDX-1307
- Telomerase
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2012
Issues and Trends
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine strategies
- New Genetic Technique
- Future Growth in Vaccines
Total Market Forecasts
- Overview
- Total market Size and Forecast
- Competitor Analysis
- Market Analysis
Corporate Profiles
- Introduction
- Advaxis, Inc.
- Antigenics, Inc.
- Aphton Corporation
- Avax Technologies, Inc.
- Biomira, Inc.
- Biovest International, Inc.
- Cell Genesys, Inc.
- Dendreon Corporation
- Favrille, Inc.
- GeneMax Corporation
- Genitope Corporation
- Genzyme Molecular Oncology
- Geron Corporation
- GlaxoSmithKline plc
- IDM Pharma, Inc.
- Intracel Resources LLC
- Large Scale Biology Corporation
- Medarex, Inc.
- MedImmune, Inc.
- Merck & Company, Inc.
- Northwest Biotherapeutics, Inc.
- Oxford BioMedica plc
- Pharmexa Group
- Progenics Pharmaceuticals, Inc.
- Therion Biologics Corporation
- Vical, Inc.
- YM BioSciences, Inc.
Company Directory
List of Exhibits
Chapter One: Executive Summary
- Figure 1-1: Market Summary: Cancer Vaccines Revenues, 2007-2012
Chapter Two: Introduction
- Table 2-1: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2005 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2005 and 2020
- Table 2-2: Estimated and Projected World Cancer Mortality by Selected
Types of Cancer, 2005 and 2020
- Figure 2-2: Estimated and Projected World Cancer Mortality by Selected
Types of Cancer, 2005 and 2020
- Table 2-3: Total Cancer Incidence by Sex and Country, 2006 Estimates
- Figure 2-3: Total Cancer Incidence by Sex and Country
- Table 2-4: Estimated Cancer Incidence by World Region and Type of Cancer
- Figure 2-4: Estimated Cancer Incidence by World Regions
- Table 2-5: World Population by Selected Geographical Region, 2006-2050
- Figure 2-5: World Population by Selected Geographical Region, 2006-2050
- Table 2-6: Estimated World Population by Age and Geographical Region, 2006
- Figure 2-6: Estimated World Population by Age and Geographical Region, 2006
- Table 2-7: Life Expectancy at Birth by Selected Countries, Projected 2006
- Table 2-8: United States Life Expectancy at Birth, 1990 and 2000;
Projections, 2006 and 2010
- Figure 2-7: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2002
- Figure 2-8: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2003
Chapter Three: Cervical Cancer Vaccines
- Table 3-1: Estimated U.S. and World Incidence and Mortality of Cervical
Cancer
- Figure 3-1: Estimated U.S. and World Incidence and Mortality of Cervical
Cancer
- Table 3-2: Cervical Cancer Vaccines in the Pipeline (Product, Developer,
Phase, Earliest Approval Date)
- Table 3-3: The World Market for Cervical Cancer Vaccines Revenues and
Growth Rate 2007-2012
- Figure 3-2: Trending in the Cervical Cancer Vaccine Market 2007-2012
- Figure 3-3: The Projected Cervical Cancer Vaccine Market in Comparison to
Traditional Therapeutics, 2012
- Table 3-4: The Cervical Cancer Vaccine Market Projected Revenues and
Market Share by Leading Supplier 2012
- Figure 3-4: Anticipated Sales by Product and Year for Cervical Cancer
Vaccines by Product, 2007-2012
Chapter Four: Colon/Rectal Cancer Vaccines
- Table 4-1: Estimated U.S. and World Incidence and Mortality of
Colon/Rectal Cancer
- Figure 4-1: Estimated U.S. and World Incidence and Mortality of
Colon/Rectal Cancer
- Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline (Product,
Developer, Phase, Earliest Approval Date)
- Table 4-3: The World Market for Colon/Rectal Cancer Vaccines Revenues and
Growth Rate 2007-2012
- Figure 4-2: Trending in the Colon/Rectal Cancer Vaccine Market, 2009-2012
- Figure 4-3: The Colon/Rectal Cancer Vaccine Market in Comparison to
Traditional Therapies, 2012
- Table 4-4: The Colon/Rectal Cancer Vaccine Market Projected Revenues and
Market Share by Leading Supplier 2012
- Figure 4-4: Anticipated Sales by Product and Year for Colon/Rectal Cancer
Vaccines, 2007-2012
Chapter Five: Lung Cancer Vaccines
- Table 5-1: Types of Primary Lung Cancer, Risk Factors, Percent of Cases
- Table 5-2: Cancer Vaccines: Estimated World Incidence and Mortality of
Lung Cancer (thousands)
- Figure 5-1: Estimated U.S. and World Incidence and Mortality of Lung Cancer
- Table 5-3: Lung Cancer Vaccines in the Pipeline (Product, Developer,
Phase, Earliest Approval Date)
- Table 5-4: The World Market for Lung Cancer Vaccines Revenues and Growth
Rate 2007-2012
- Figure 5-2: Trending in the Lung Cancer Vaccine Market, 2009-2012
- Figure 5-3: The Lung Cancer Vaccine Market in Comparison to Traditional
Therapies, 2012
- Table 5-5: The Lung Cancer Vaccine Market Projected Revenues and Market
Share by Leading Supplier 2012
- Figure 5-4: Anticipated Sales by Product and Year for Lung Cancer Vaccines
2009-2012
Chapter Six: Lymphoma Vaccines
- Table 6-1: Classification of Non-Hodgkin' s Lymphomas
- Table 6-2: Estimated U.S. and World Incidence and Mortality of Lymphoma
- Figure 6-1: Estimated U.S. and World Incidence and Mortality of Lymphoma
- Table 6-3: Lymphoma Vaccines in the Pipeline (Product, Developer, Phase,
Earliest Approval Date)
- Table 6-4: The World Market for Lymphoma Vaccines Revenues and Growth Rate
2007-2012
- Figure 6-2: Trending in the Lymphoma Vaccine Market, 2008-2012
- Figure 6-3: The Lymphoma Vaccine Market in Comparison to Traditional
Therapies, 2012
- Table 6-5: The Lymphoma Vaccine Market Projected Revenues and Market Share
by Leading Supplier 2012
- Figure 6-4: Anticipated Sales by Product and Year for Emerging Lymphoma
Vaccines, 2008-2012
Chapter Seven: Melanoma Vaccines
- Table 7-1: Malignant Conditions of the Skin
- Table 7-2: Estimated U.S. and World Incidence and Mortality of Melanoma
- Figure 7-1: Estimated U.S. and World Incidence and Mortality of Melanoma
- Table 7-3: Melanoma Vaccines in the Pipeline (Product, Developer, Phase,
Earliest Approval Date)
- Table 7-4: The World Market for Melanoma Vaccines Revenues and Growth Rate
2007-2012
- Figure 7-2: Trending in the Melanoma Vaccine Market, 2007-2012
- Figure 7-3: The Melanoma Vaccine Market in Comparison to Traditional
Therapies, 2012
- Table 7-5: The Melanoma Vaccine Market Projected Revenues and Market Share
by Leading Supplier 2012
- Figure 7-4: Anticipated Sales by Product and Year for Melanoma Vaccines
2007-2012
Chapter Eight: Prostate Cancer Vaccines
- Table 8-1: Estimated U.S and World Incidence and Mortality of Prostate
Cancer
- Figure 8-1: Estimated U.S. and World Incidence and Mortality of Prostate
Cancer
- Table 8-2: Prostate Cancer Vaccines in the Pipeline (Product, Developer,
Phase, Earliest Approval Date)
- Table 8-3: The World Market for Prostate Cancer Vaccines Revenues and
Growth Rate 2007-2012
- Figure 8-2: Trending in the Prostate Cancer Vaccine Market, 2008-2012
- Figure 8-3: The Prostate Cancer Vaccine Market in Comparison to
Traditional Therapies, 2012
- Table 8-4: The Prostate Cancer Vaccine Market Projected Revenues and
Market Share by Leading Supplier 2012
- Figure 8-4: Anticipated Sales by Product and Year for Prostate Cancer
Vaccines, 2007-2012
Chapter Nine: Various Cancer Vaccines
- Table 9-1: Types of Leukemia (Incidence, Age of Onset, Clinical
Manifestations)
- Table 9-2: Estimated U.S. World Incidence and Mortality of Various Cancers
(Bladder, Breast, Kidney, Leukemia, Liver, Neuroblastoma, Ovarian, Pancreatic,
Stomach)
- Figure 9-1: Estimated U.S. and World Incidence and Mortality of Various
Cancer
- Table 9-3: Various Cancer Vaccines in the Pipeline (Product, Developer,
Phase, Cancer Type, Earliest Approval Date)
- Table 9-4: The World Market for Other Cancer Vaccines Revenues and Growth
Rate 2007-2012
- Figure 9-2: Trending in the Market for Other Cancer Vaccines 2007-2012
- Figure 9-3: The Emerging Various Cancer Vaccine Market in Comparison to
Traditional Therapies, 2012
- Table 9-5: Projected Revenues and Market Share of Leading Suppliers of
Other Cancer Vaccines 2012
- Figure 9-4: Anticipated Sales by Product and Year for Other Cancer
Vaccines, 2007-2012
Chapter Ten: Issues and Trends
- Table 10-1: Cancer Detection Tests
Chapter Eleven: Total Market Forecasts
- Table 11-1: Cancer Vaccines Market by Cancer Type, 2007-2012
- Figure 11-1: Trending in the Cancer Vaccines Market, 2007-2012
- Figure 11-2: Share of the Cancer Vaccine by Vaccine Indication, 2012
- Table 11-2: Suppliers/Developers of Vaccines by Cancer Type and
Development Phase
- Figure 11-3: Number of Cancer Vaccine Trials by Cancer Type
- Figure 11-4: Cancer Vaccine Trials, Distribution by Cancer Type, 2006
- Figure 11-5: Cancer Vaccines in Development by Type and Phase
- Figure 11-6: Cancer Vaccines in Developments by Phase, 2006
|
Related Report
|
View Cart
